Oncomed Pharmaceuticals Inc., of Redwood City, Calif. said the FDA removed a partial clinical hold on a phase I trial of ipafricept, its Leverukusen, Germany-based Bayer AG-partnered Wnt pathway inhibitor, after providing the agency with safety and efficacy data and revised study protocols.